<DOC>
	<DOCNO>NCT01456117</DOCNO>
	<brief_summary>The purpose study assess effect pioglitazone , daily ( QD ) , brain hemodynamics healthy elderly participant .</brief_summary>
	<brief_title>Study Assess Effects Daily Administration Pioglitazone Brain Hemodynamics Healthy Elderly Participants</brief_title>
	<detailed_description>The study evaluate effect resting-state network therapeutic intervention , also task-related brain network specific cognitive challenge .</detailed_description>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . The participant healthy adult male female participant age 55 83 year , inclusive , time informed consent first dose study medication dose . 4 . Female participant childbearing potential include study . Female participant must postmenopausal ( define &gt; 2 year without menses ) . 5 . The participant consider normal cognitive ability , assessed standard cognitive test administer Screening visit . All participant undergo brief neuropsychological assessment include Montreal Cognitive Assessment ( MoCA ) Alzheimer Disease Cooperative Study Cognitive Function Screening Instrument verify general cognitive status . Memory assess Consortium Establish Registry Alzheimer 's Disease ( CERAD ) Word List Memory Test Trail Making Part B . Normal performance define score within 1 standard deviation ( SD ) age education normative mean . 1 . The participant receive pioglitazone thiazolidinedione ( TZD ) previous clinical study therapeutic agent within 1 year Screening . 2 . The participant immediate family member , study site employee ( define study personnel employee directly supervise study personnel ) , dependant relationship study site employee involve conduct study ( e.g. , spouse , parent , child , sibling ) may consent duress . 3 . The participant uncontrolled , clinically significant neurologic ( e.g. , migraine well control , narcolepsy , previous head injury loss consciousness , seizure ) , osteoporosis , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , endocrine disease abnormality may impact ability participant participate potentially confound study result . 4 . Participant know hypersensitivity allergy component formulation pioglitazone related compound . 5 . The participant history drug abuse ( define illicit drug use ) history alcohol abuse within 1 year prior Screening visit unwilling agree abstain alcohol drug throughout study . Participant unwilling agree abstain alcohol 24 hour prior MRI unwilling abstain drug throughout study . 6 . History evidence central nervous system disorder could interpret cause dementia . 7 . Current diagnosis significant psychiatric disorder accord Diagnostic Statistical Manual Mental Disorders Forth Edition Text Revision ( DSMIVTR ) . Subjects recent/past psychiatric disorder currently remission/asymptomatic without use medication may eligible determined principal investigator medical monitor . 8 . Diabetes mellitus participant treat insulin and/or peroxisome proliferatoractivated receptorɣ ( PPARɣ ) agonist . 9 . Participant history cancer require chemotherapy treatment within past 2 year prior Day 1 , metastatic cancer past 5 year prior Day 1 , radiation treatment brain lifetime . Subjects basal cell stage I squamous cell carcinoma skin eligible . Eligibility subject history cancer determine principal investigator medical monitor.10 . History macular edema , degeneration maculopathy . 11 . Participant glycosylated hemoglobin ( HbA1c ) ≥6 % . 12 . Participant congestive heart failure significant edema ( 2+ ) extremity . 13 . History postmenopausal bone fracture ( female ) . 14 . If male , participant intend donate sperm course study 30 day last dose study drug . 15 . Participant current recent ( within 6 month ) gastrointestinal disease would expect influence absorption drug ( i.e. , history malabsorption , esophageal reflux , peptic ulcer disease , erosive esophagitis , frequent [ per week ] occurrence heartburn , surgical intervention [ e.g. , cholecystectomy ] ) . 16 . Participant positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( antiHCV ) Screening know history human immunodeficiency virus infection ( HIV ) . 17 . Participant Screening Checkin ( Day 1 ) abnormal ( clinically significant ) ECG . ( Entry participant abnormal ( clinically significant ) ECG must approve , document signature principal investigator . ( If principal investigator MD , ECG must assess qualified investigator ) . 18 . Participant abnormal Screening Day 1 laboratory value suggest clinically significant underlying disease participant follow lab abnormality : Alanine Aminotransferase ( ALT ) and/or Aspartate Aminotransferase ( AST ) &gt; 2x upper limit normal ( ULN ) . 19 . Participant contraindication MRI , example ferromagnetic foreign body ( e.g. , unremovable ferromagnetic dental work ) , medical device aneurysm clip cardiac pacemaker , leadbased tattoo . 20 . Participant hematuria ( microscopic macroscopic ) Screening .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>83 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Drug Therapy</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>